GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ELMD · Mar 31, 2023

Electromed, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000897101-23-000192General Corporate
Revenue growth95thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

19.00% · CORE · VALID

Inventory pressure50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

28.60% · OPTIONAL · VALID

Gross margin5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

75.04% · CORE · VALID

Operating margin60thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

9.91% · CORE · VALID

R&D intensity25thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1.38% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History60 statesSelf-history eligible
Period transition

What moved in the state?

Growth Increased
Previous
14.45%
Current
19.00%
Delta
4.55%
Inventory Pressure Decreased
Previous
29.61%
Current
28.60%
Delta
-1.01%
Margin Increased
Previous
74.02%
Current
75.04%
Delta
1.02%
Profitability Decreased
Previous
10.86%
Current
9.91%
Delta
-0.95%
R And D Intensity Increased
Previous
1.31%
Current
1.38%
Delta
0.06%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.